(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 May 2014 (15.05.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/073842 A1

(51) International Patent Classification:
A61K 9/08 (2006.01) *C07K 14/605* (2006.01)
A61K 38/26 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/KR2013/009986

(22) International Filing Date:
6 November 2013 (06.11.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2012-0124725 6 November 2012 (06.11.2012) KR

(71) Applicant: **HANMI PHARM. CO., LTD.** [KR/KR]; 214, Muha-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do 445-958 (KR).

(72) Inventors: **KIM, Hyun Uk**; 132-2604, 232, Dongtan-banseok-ro, Hwaseong-si, Gyeonggi-do 445-856 (KR). **LIM, Hyung Kyu**; 409-904, 78, Byeongjeom 2-ro, Hwaseong-si, Gyeonggi-do 445-763 (KR). **JANG, Myung Hyun**; 137-2403, 131, Godeok-ro, Gangdong-gu, Seoul 134-715 (KR). **KIM, Sang Yun**; 101-1301, 16, Gamjeong-ro 38beon-gil, Gimpo-si, Gyeonggi-do 415-010 (KR). **BAE, Sung Min**; 205-603, 143, Jeongja-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-909 (KR). **KWON, Se Chang**; 408-1804, 221, Seolleung-ro, Gangnam-gu, Seoul 135-506 (KR).

(74) Agent: **SON, Min**; Hanol Intellectual Property & Law, STX R&D Center, 6th Floor, 163, YangJaeCheon-ro, Gangnam-gu, Seoul 135-855 (KR).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

[Continued on next page]

(54) Title: LIQUID FORMULATION OF PROTEIN CONJUGATE COMPRISING THE OXYNTOMODULIN AND AN IMMUNOGLOBULIN FRAGMENT

[Fig. 2a]



(57) Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the *invivo* stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection. In addition, the oxyntomodulin conjugate of the invention comprises oxyntomodulin linked to an immunoglobulin Fc region, and thus has a large molecular weight, prolonged physiological activity, and excellent storage stability, compared to native oxyntomodulin.

WO 2014/073842 A1

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*